Operational Costs Compared: SG&A Analysis of AbbVie Inc. and Catalyst Pharmaceuticals, Inc.

A Decade of SG&A: AbbVie vs. Catalyst Pharmaceuticals

In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. Over the past decade, AbbVie Inc. and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. AbbVie, a global biopharmaceutical leader, has seen its SG&A expenses grow by approximately 66% from 2014 to 2023, peaking in 2022. This increase reflects its expansive operations and strategic investments. In contrast, Catalyst Pharmaceuticals, a smaller player, has experienced a staggering 2,887% rise in SG&A expenses over the same period, highlighting its aggressive growth strategy. By 2023, Catalyst's SG&A expenses reached a notable milestone, indicating its commitment to scaling operations. This analysis underscores the diverse strategies employed by pharmaceutical companies to navigate market challenges and opportunities.